Drug reference

lifitegrast

LFA-1 antagonist · Immunomodulator

LFA-1 antagonistImmunomodulator

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Inhibits an integrin, lymphocyte function–associated antigen 1 (LFA-1), from binding to intercellular adhesion molecule 1 (ICAM-1), which is thought to downregulate inflammation mediated by T lymphocytes.

Indications

dry eye disease (signs and symptoms)

Related guidelines

Coeliac disease

OTHER · Gastroenterology · 2016

Inflammatory bowel disease

OTHER · Gastroenterology · 2015

Chronic kidney disease — assessment and management

KDIGO · Nephrology · 2024

Gastro-oesophageal reflux disease

ISG · Gastroenterology · 2022

Glomerular diseases

KDIGO · Nephrology · 2021

Ask House about lifitegrast

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team